Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $40.27 USD
Change Today -1.98 / -4.69%
Volume 715.8K
SGEN On Other Exchanges
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Clay B. Siegall Ph.D.

Co-Founder, Chairman, Chief Executive Officer and President,Seattle Genetics, Inc.
AgeTotal Calculated CompensationThis person is connected to 41 board members in 4 different organizations across 4 different industries.

See Board Relationships
As of Fiscal Year 2014


Dr. Clay B. Siegall, Ph.D., co-founded Seattle Genetics, Inc. in 1997 and has been its Chief Executive Officer since November 2002 and President since June 2000. Dr. Siegall has nearly 20 years of experience in cancer research and therapeutic drug development. Dr. Siegall served as Executive Vice President of Seattle Genetics Inc., from December 1997 to June 2000 and Chief Scientific Officer from December 1997 to November 2002. Dr. Siegall was with the Bristol-Myers ...

Read Full Background

Corporate Headquarters*

21823 30th Drive SE
Bothell, Washington 98021

United States

Phone: 425-527-4000
Fax: 425-527-4001

Board Members Memberships*

Co-Founder, Chairman, Chief Executive Officer and President
Director and Chairman of Compensation Committee
Independent Director and Member of Compensation Committee


George Washington University
University of Maryland

Other Affiliations*

Annual Compensation*

Total Annual Compensation$759,250

Stock Options*

Restricted Stock Awards$2,645,400
All Other Compensation$8,280
Exercised Options56,918
Exercised Options Value$2,164,730
Exercisable Options1,702,200
Exercisable Options Value$32,883,490
Unexercisable Options369,011
Unexercisable Options Value$1,299,884
Total Value of Options$36,348,104
Total Number of Options2,128,129

Total Compensation*

Total Annual Cash Compensation$1,414,330
Total Short Term Compensation$759,250
Other Long Term Compensation$2,653,680
Total Calculated Compensation$6,863,212
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGEN:US $40.27 USD -1.98


Harvey J. Berger M.D.Principal Founder, Chairman, Chief Executive Officer and President
Ariad Pharmaceuticals Inc.
Jan G. J. van de Winkel Ph.D.Co-Founder, Chief Executive Officer and President
Genmab A/S
Aijaz Tobaccowalla Managing Director, Director, Member of Board Administrative & Share Transfer Committee, Member of Nomination & Remuneration Committee, Member of Corporate Social Responsibility Committee and Member of Audit Committee
Pfizer Limited
David T. Hung M.D.Founder, Chief Executive Officer, President and Executive Director
Medivation, Inc.
Michael L. Babich Chief Executive Officer, President and Director
INSYS Therapeutics, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEATTLE GENETICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at